PD-1/PD-L1抑制剂在卵巢癌中的研究进展  

Research progress of PD-1/PD-L1 inhibitors in ovarian cancer

作　　者：薛晨 赵月[1] 石光[1] 唐艳[1] Xue Chen;Zhao Yue;Shi Guang;Tang Yan(Department of Oncology and Hematology,Second Hospital of Jilin University,Changchun 130041,China)

机构地区：[1]吉林大学第二医院肿瘤血液科,长春130041

出　　处：《国际肿瘤学杂志》2020年第5期312-315,共4页Journal of International Oncology

基　　金：吉林省科技厅国际合作项目(20180414084GH)。

摘　　要：卵巢癌具有早期诊断困难、易复发、易耐药等特点,其病死率居于妇科肿瘤的首位。现有的手术及放化疗等治疗方法效果欠佳,免疫治疗应运而生。免疫检查点程序性死亡蛋白-1(PD-1)及其配体PD-L1可抑制T细胞增殖、介导肿瘤免疫逃逸。目前,PD-1/PD-L1抑制剂已在多种实体瘤中取得突破性进展,其在卵巢癌临床治疗中也取得初步疗效。Ovarian cancer has the characteristics of difficulty in early diagnosis,easy recurrence and resistance,so its mortality rate ranks first in gynecological tumors.Existing treatment methods such as surgery,radiotherapy and chemotherapy are not very effective,thus immunotherapy has emerged.Immune checkpoint programmed death-1(PD-1)and its ligand PD-L1 can inhibit T cell proliferation and mediate tumor immune escape.At present,PD-1/PD-L1 inhibitors have made breakthrough progress in a variety of solid tumors,and they have achieved initial efficacy in clinical treatment of ovarian cancer.

关 键 词：卵巢肿瘤 免疫疗法 PD-1 PD-L1 

分 类 号：R737.31[医药卫生—肿瘤]